HOME >> BIOLOGY >> NEWS
Final results demonstrate Aranesp dosed every two weeks is comparable to Epoetin alfa dosed weekly

ORLANDO, Fla., (May 15, 2005) Amgen Inc., (NASDAQ: AMGN) the world's largest biotechnology company, today announced that final results of a Phase 3 randomized, head-to-head study demonstrated that 200 mcg of Aranesp (darbepoetin alfa) administered every two weeks is as effective as 40,000 U of Epoetin alfa dosed once a week in boosting hemoglobin levels and reducing the need for red blood cell transfusions in cancer patients with chemotherapy-induced anemia. The data were presented today at the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO). [Abstract #8125]

"This is the largest, randomized head-to-head comparison of darbepoetin alfa dosed every two weeks to Epoetin alfa dosed weekly, as they are most often used in current oncology practice," said John Glaspy, MD, professor, David Geffen School of Medicine, University of California at Los Angeles. "Less frequent dosing provides anemia management with less frequent injections, and for patients receiving chemotherapy every two or three weeks, less frequent office visits. Our data demonstrate that less frequent injections can be accomplished without a compromise in efficacy in terms of decreased transfusion risk or improved quality of life."

In the Phase 3 head-to-head study, a total of 1,220 patients with chemotherapy-induced anemia were randomized to receive either Aranesp 200 mcg every two weeks (n=613) or Epoetin alfa 40,000 U once a week (n=607). The majority of patients in both groups achieved the target hemoglobin of greater than or equal to 11 g/dL. Both groups of patients had similar blood transfusion rates, patient reported outcomes, and safety endpoints.

In this study, at least 90 percent of patients in both arms of the study achieved target hemoglobin of greater than or equal to 11 g/dL. Seventy-four percent of patients in the Aranesp group remained in the target range compared to 80 percent in the Epoetin alfa group. The study's primary endpoi
'"/>

Contact: Trish Hawkins
805-447-4587
Porter Novelli
16-May-2005


Page: 1 2

Related biology news :

1. Final of the 2005-06 Research Councils Business Plan Competition
2. Finally, JAP study shows headdown bedrest precisely mimics human physiology in spaceflight
3. Finally, male water fleas exposed
4. Finalists in young scholars competition announced
5. Cooperative science program yields results
6. Delayed treatment of childhood-onset bipolar disorder results in negative outcome in adults
7. Smelling for first time results from knowing abnormalities in congenital loss of smell
8. BDSI announces positive phase III clinical trial results
9. Scientists meet to review Envisat results after 5 years of operations
10. Environment and exercise may affect research results, UA study shows
11. Preliminary results of largest scan of autism DNA information

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/31/2018)... Calif. (PRWEB) , ... July 31, 2018 , ... ... to connect seamlessly with LabArchives , the leading cloud-based Electronic Lab Notebook (ELN) ... and LabArchives enables researchers to store all of their research data records in a ...
(Date:7/30/2018)... ... July 30, 2018 , ... ... the beneficial impact of biofield energy healing treated Vitamin D3 on the strength ...     Over 260% increase in ALP, a bone-specific enzyme , ...
(Date:7/28/2018)... ... , ... Professor You-Lin Xu, Dean of Faculty of Construction ... the International Association for Wind Engineering (IAWE) Senior Award (Davenport Medal) for his ... education, and application. Professor Xu is the first scholar in Hong Kong, and ...
Breaking Biology News(10 mins):
(Date:8/9/2018)... (PRWEB) , ... August 08, 2018 , ... ... GenoACT service was developed and is continually updated by a talented scientific team ... The integrated service provides: , 1. Information on the medical impact of ...
(Date:8/9/2018)... ... August 09, 2018 , ... Rockland ... and Dr. Birte Aggeler, Director of Antibody Development at Bio-Techne, composed a peer-reviewed ... was published online on August 9, 2018 and will be printed in the ...
(Date:8/1/2018)... (PRWEB) , ... August 01, ... ... healer, today announces research results on the significant impact of a proprietary ... responses. , The preclinical research assessed biomarkers for systemic and organ-specific ...
(Date:7/27/2018)... ... July 27, 2018 , ... ... representatives of the Biotechnology Innovation Organization (BIO) met with U.S. Environmental Protection ... for a Toxic Substances Control Act (TSCA) Inventory Representation and Equivalency Determinations ...
Breaking Biology Technology:
Cached News: